Deep Vein Thrombosis of Saphenous-Femoral Junction After Leg Lauromacrogol Foam Ultrasound Guided Percutaneous Sclerotherapy

Marco Quarato(1*), Ilaria Lacavalla(2)


(1) Local Health Unit of Bari Traversa di via Rimembranza 14 70015 Noci(BA), Italy
(2) Local Health Unite of Bari, ”Di Venere“ Hospital, 70012, Bari, Italy
(*) Corresponding Author

Abstract


Background: Lauromacrogol foam sclerotherapy is characterized by a high success rate in obliterating varicose veins and a low frequency of adverse effects. Most of these parts consist of minor effects, and few data are available about significant effects (e.g., vein thrombosis), pointing out the technical safety of ultrasound-guided foam sclerotherapy.

Case Presentation: a 78-year-old woman was evaluated for chronic vein disease; at ultrasonographic and Doppler scan (USDS), severe GSV dilatation and GSV reflux were documented in both legs below the knee. After meticulous anamnesis and physical examination, informed consent was obtained, and ultrasound-guided percutaneous polidocanol foam (one part of 2% lauromacrogol solution + one part of the air, mixed with Double Syringe System) sclerotherapy was performed in the right leg; best medical therapy was given after the procedure. After five days, USDS pointed out thrombosis extending to the thigh upper region to saphenous-femoral junctions, consisting of deep vein thrombosis. Appropriate anticoagulant therapy was promptly dispensed, and the patient had no aftermaths.

Conclusion:The prevalence of vein thrombosis after lauromacrogol sclerotherapy is unknown, and their correlation is uncertain, but, in our experience, it should be suspected in patients who referred lower limb pain after this procedure despite the best medical therapy dispensation.  

 


Keywords


foam sclerotherapy; deep vein thrombosis; ultrasound; lauromacrogol

Full Text:

PDF

References


Beebe-Dimmer JL, Pfeifer JR, Engle JS, Schottenfeld D. The epidemiology of chronic venous insufficiency and varicose veins. Annals of Epidemiology. 2005;15(3):175–84.

Criqui MH, Jamosmos M, Fronek A, Denenberg JO, Langer RD, Bergan J, et al. Chronic venous disease in an ethnically diverse population: The San Diego population study. American Journal of Epidemiology. 2003;158(5):448–56.

Meissner MH, Moneta G, Burnand K, Gloviczki P, Lohr JM, Lurie F, et al. The hemodynamics and diagnosis of venous disease. Journal of Vascular Surgery. 2007;46(6 SUPPL.):S4–24.

Eberhardt RT, Raffetto JD. Chronic venous insufficiency. Circulation. 2014;130(4):333–46.

Raffetto JD, Ligi D, Maniscalco R, Khalil RA, Mannello F. Why venous leg ulcers have difficulty healing: Overview on pathophysiology, clinical consequences, and treatment. Journal of Clinical Medicine. 2021;10(1):1–33.

Kundu S, Lurie F, Millward SF, Padberg F, Vedantham S, Elias S, et al. Recommended Reporting Standards for Endovenous Ablation for the Treatment of Venous Insufficiency: Joint Statement of the American Venous Forum and the Society of Interventional Radiology. Journal of Vascular and Interventional Radiology. 2009;20(7 SUPPL.):582–9.

Mozes G, Kalra M, Carmo M, Swenson L, Gloviczki P. Extension of saphenous thrombus into the femoral vein: A potential complication of new endovenous ablation techniques. Journal of Vascular Surgery. 2005;41(1):130–5.

Eckmann DM, Kobayashi S, Li M. Microvascular embolization following polidocanol microfoam sclerosant administration. Dermatologic Surgery. 2005;31(6):636–43.

Parsi K, Exner T, Connor DE, Herbert A, Ma DDF, Joseph JE. The Lytic Effects of Detergent Sclerosants on Erythrocytes, Platelets, Endothelial Cells and Microparticles are Attenuated by Albumin and other Plasma Components in Vitro. European Journal of Vascular and Endovascular Surgery. 2008;36(2):216–23.

Bergan J. Immediate and midterm complications of sclerotherapy: Report of a prospective multicenter registry of 12,173 sclerotherapy sessions. Commentary. Dermatologic Surgery. 2005;31(2):128.

Carugo D, Ankrett DN, Zhao X, Zhang X, Hill M, O’Byrne V, et al. Benefits of polidocanol endovenous microfoam (Varithena®) compared with physician-compounded foams. Phlebology. 2016;31(4):283–95.

Li N, Li J, Huang M, Zhang X. Efficacy and safety of polidocanol in the treatment of varicose veins of lower extremities: A protocol for systematic review and meta-analysis. Medicine. 2021 Feb;100(8):e24500.

Carlton R, Mallick R, Campbell C, Raju A, O’Donnell T, Eaddy M. Evaluating the expected costs and budget impact of interventional therapies for the treatment of chronic venous disease. American Health and Drug Benefits. 2015;8(7):366–74.

Eckmann DM. Polidocanol for endovenous microfoam sclerosant therapy. Expert Opinion on Investigational Drugs. 2009;18(12):1919–27.

Jamil AM, Putra MA, Anas M. Adobe Photoshop Express Application Enhances the Diagnosis of X-Ray Thorax of Covid-19 Patient. Indonesian Journal of Medical Sciences and Public Health. 2021;1(2):54–61.


Article Metrics

Abstract view : 67 times
PDF - 9 times

DOI: https://doi.org/10.26714/magnamed.11.1.2024.108-113

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Indexed by

 

      

 

Creative Commons License

MAGNA MEDIKA by APKKM is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.